vs
Archrock, Inc.（AROC）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
Archrock, Inc.的季度营收约是Orthofix Medical Inc.的1.7倍（$377.1M vs $219.9M），Archrock, Inc.净利率更高（31.0% vs -1.0%，领先32.0%），Archrock, Inc.同比增速更快（15.5% vs 2.0%），Archrock, Inc.自由现金流更多（$126.7M vs $16.8M），过去两年Archrock, Inc.的营收复合增速更高（18.5% vs 8.0%）
Archrock, Inc. 是领先的天然气压缩服务及相关设备解决方案供应商，主要服务北美油气领域，核心业务涵盖压缩系统租赁、维护、售后支持及销售，覆盖上游生产、中游运输与天然气加工板块。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
AROC vs OFIX — 直观对比
营收规模更大
AROC
是对方的1.7倍
$219.9M
营收增速更快
AROC
高出13.5%
2.0%
净利率更高
AROC
高出32.0%
-1.0%
自由现金流更多
AROC
多$109.9M
$16.8M
两年增速更快
AROC
近两年复合增速
8.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $377.1M | $219.9M |
| 净利润 | $116.8M | $-2.2M |
| 毛利率 | 53.0% | 71.1% |
| 营业利润率 | 39.4% | 0.2% |
| 净利率 | 31.0% | -1.0% |
| 营收同比 | 15.5% | 2.0% |
| 净利润同比 | 95.4% | 92.4% |
| 每股收益（稀释后） | $0.67 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AROCOFIX
| Q4 25 | $377.1M | $219.9M | ||
| Q3 25 | $382.4M | $205.6M | ||
| Q2 25 | $383.2M | $203.1M | ||
| Q1 25 | $347.2M | $193.6M | ||
| Q4 24 | $326.4M | $215.7M | ||
| Q3 24 | $292.2M | $196.6M | ||
| Q2 24 | $270.5M | $198.6M | ||
| Q1 24 | $268.5M | $188.6M |
净利润AROCOFIX
| Q4 25 | $116.8M | $-2.2M | ||
| Q3 25 | $71.2M | $-22.8M | ||
| Q2 25 | $63.4M | $-14.1M | ||
| Q1 25 | $70.8M | $-53.1M | ||
| Q4 24 | $59.8M | $-29.1M | ||
| Q3 24 | $37.5M | $-27.4M | ||
| Q2 24 | $34.4M | $-33.4M | ||
| Q1 24 | $40.5M | $-36.0M |
毛利率AROCOFIX
| Q4 25 | 53.0% | 71.1% | ||
| Q3 25 | 48.5% | 72.2% | ||
| Q2 25 | 45.4% | 68.7% | ||
| Q1 25 | 47.4% | 62.8% | ||
| Q4 24 | 46.3% | 69.0% | ||
| Q3 24 | 44.4% | 68.7% | ||
| Q2 24 | 41.5% | 67.8% | ||
| Q1 24 | 42.1% | 67.5% |
营业利润率AROCOFIX
| Q4 25 | 39.4% | 0.2% | ||
| Q3 25 | 25.3% | -8.3% | ||
| Q2 25 | 22.5% | -7.9% | ||
| Q1 25 | 26.5% | -25.2% | ||
| Q4 24 | 24.0% | -5.3% | ||
| Q3 24 | 18.1% | -9.6% | ||
| Q2 24 | 17.6% | -12.5% | ||
| Q1 24 | 20.0% | -15.6% |
净利率AROCOFIX
| Q4 25 | 31.0% | -1.0% | ||
| Q3 25 | 18.6% | -11.1% | ||
| Q2 25 | 16.6% | -6.9% | ||
| Q1 25 | 20.4% | -27.4% | ||
| Q4 24 | 18.3% | -13.5% | ||
| Q3 24 | 12.8% | -13.9% | ||
| Q2 24 | 12.7% | -16.8% | ||
| Q1 24 | 15.1% | -19.1% |
每股收益（稀释后）AROCOFIX
| Q4 25 | $0.67 | $-0.05 | ||
| Q3 25 | $0.40 | $-0.57 | ||
| Q2 25 | $0.36 | $-0.36 | ||
| Q1 25 | $0.40 | $-1.35 | ||
| Q4 24 | $0.35 | $-0.76 | ||
| Q3 24 | $0.22 | $-0.71 | ||
| Q2 24 | $0.22 | $-0.88 | ||
| Q1 24 | $0.26 | $-0.95 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.6M | $82.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.5B | $450.0M |
| 总资产 | $4.3B | $850.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资AROCOFIX
| Q4 25 | $1.6M | $82.0M | ||
| Q3 25 | $4.1M | $62.9M | ||
| Q2 25 | $5.9M | $65.6M | ||
| Q1 25 | $4.8M | $58.0M | ||
| Q4 24 | $4.4M | $83.2M | ||
| Q3 24 | $3.7M | $30.1M | ||
| Q2 24 | $919.0K | $26.4M | ||
| Q1 24 | $1.2M | $27.0M |
总债务AROCOFIX
| Q4 25 | — | — | ||
| Q3 25 | — | $157.2M | ||
| Q2 25 | — | $157.0M | ||
| Q1 25 | — | $156.9M | ||
| Q4 24 | — | $157.0M | ||
| Q3 24 | — | $118.5M | ||
| Q2 24 | — | $118.0M | ||
| Q1 24 | — | $118.2M |
股东权益AROCOFIX
| Q4 25 | $1.5B | $450.0M | ||
| Q3 25 | $1.4B | $442.5M | ||
| Q2 25 | $1.4B | $458.3M | ||
| Q1 25 | $1.3B | $458.3M | ||
| Q4 24 | $1.3B | $503.1M | ||
| Q3 24 | $1.3B | $525.9M | ||
| Q2 24 | $894.5M | $546.0M | ||
| Q1 24 | $882.1M | $570.3M |
总资产AROCOFIX
| Q4 25 | $4.3B | $850.6M | ||
| Q3 25 | $4.4B | $832.6M | ||
| Q2 25 | $4.4B | $837.2M | ||
| Q1 25 | $4.0B | $823.1M | ||
| Q4 24 | $3.8B | $893.3M | ||
| Q3 24 | $3.8B | $867.9M | ||
| Q2 24 | $2.7B | $882.0M | ||
| Q1 24 | $2.7B | $906.0M |
负债/权益比AROCOFIX
| Q4 25 | — | — | ||
| Q3 25 | — | 0.36× | ||
| Q2 25 | — | 0.34× | ||
| Q1 25 | — | 0.34× | ||
| Q4 24 | — | 0.31× | ||
| Q3 24 | — | 0.23× | ||
| Q2 24 | — | 0.22× | ||
| Q1 24 | — | 0.21× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $214.5M | $27.7M |
| 自由现金流经营现金流 - 资本支出 | $126.7M | $16.8M |
| 自由现金流率自由现金流/营收 | 33.6% | 7.6% |
| 资本支出强度资本支出/营收 | 23.3% | 4.9% |
| 现金转化率经营现金流/净利润 | 1.84× | — |
| 过去12个月自由现金流最近4个季度 | $119.6M | $-1.3M |
8季度趋势，按日历期对齐
经营现金流AROCOFIX
| Q4 25 | $214.5M | $27.7M | ||
| Q3 25 | $164.5M | $12.4M | ||
| Q2 25 | $127.5M | $11.6M | ||
| Q1 25 | $115.6M | $-18.4M | ||
| Q4 24 | $124.3M | $23.7M | ||
| Q3 24 | $96.9M | $11.7M | ||
| Q2 24 | $70.7M | $9.0M | ||
| Q1 24 | $137.7M | $-18.6M |
自由现金流AROCOFIX
| Q4 25 | $126.7M | $16.8M | ||
| Q3 25 | $29.5M | $2.5M | ||
| Q2 25 | $16.0M | $4.5M | ||
| Q1 25 | $-52.5M | $-25.1M | ||
| Q4 24 | $26.4M | $15.2M | ||
| Q3 24 | $26.9M | $6.3M | ||
| Q2 24 | $-20.6M | $-360.0K | ||
| Q1 24 | $37.9M | $-29.1M |
自由现金流率AROCOFIX
| Q4 25 | 33.6% | 7.6% | ||
| Q3 25 | 7.7% | 1.2% | ||
| Q2 25 | 4.2% | 2.2% | ||
| Q1 25 | -15.1% | -13.0% | ||
| Q4 24 | 8.1% | 7.0% | ||
| Q3 24 | 9.2% | 3.2% | ||
| Q2 24 | -7.6% | -0.2% | ||
| Q1 24 | 14.1% | -15.4% |
资本支出强度AROCOFIX
| Q4 25 | 23.3% | 4.9% | ||
| Q3 25 | 35.3% | 4.8% | ||
| Q2 25 | 29.1% | 3.5% | ||
| Q1 25 | 48.4% | 3.5% | ||
| Q4 24 | 30.0% | 4.0% | ||
| Q3 24 | 24.0% | 2.7% | ||
| Q2 24 | 33.7% | 4.7% | ||
| Q1 24 | 37.2% | 5.6% |
现金转化率AROCOFIX
| Q4 25 | 1.84× | — | ||
| Q3 25 | 2.31× | — | ||
| Q2 25 | 2.01× | — | ||
| Q1 25 | 1.63× | — | ||
| Q4 24 | 2.08× | — | ||
| Q3 24 | 2.58× | — | ||
| Q2 24 | 2.05× | — | ||
| Q1 24 | 3.40× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AROC
| Horsepower Group Three | $112.6M | 30% |
| Horsepower Group Two | $108.5M | 29% |
| Horsepower Group One | $105.9M | 28% |
| Services | $32.9M | 9% |
| Over Counter Parts And Component Sales | $17.0M | 5% |
| Transferred At Point In Time | $1.4M | 0% |
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
